Six patients had SD with INCAGN02385 treatment; 5 of these patients had received previous treatment with a PD-1-targeted ICI (nivolumab or pembrolizumab), including one patient with hepatocellular carcinoma who had SD with combined PD-1 plus CTLA-4-targeted treatment (nivolumab plus ipilimumab). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.